Armetheon closes $24 million Series B financing
Menlo Park, CA – February 5, 2015 – Armetheon, Inc., a cardiovascular disease-focused, clinical stage, specialty biopharmaceutical company, today announced the successful closing of $24.3 million in Series B financing. The financing was co-led by Hercules Bioventure...
read moreArmetheon Completes $7.0 Million Series A Financing
Menlo Park, CA – August 28, 2014 --- Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The...
read moreAshHill Biomedical Investments announces recent regulatory approvals for several ventures
Cincinnati, Ohio – AshHill Biomedical Investments, a U.S.-based private investment firm specializing in biomedical opportunities, announced several of its ventures recently passed significant FDA approval hurdles – including Orphan Drug Designation for a medication...
read more2014 Newsletter
In this edition: Sinusys earns FDA clearance for its Vent-Os Sinus Dilation System. Heart Metabolics is awarded Orphan Drug Designation for a medication to treat hypertrophic cardiomyopathy. Armetheon has completed a Special Protocol Assessment for its anticoagulant....
read more2013 Newsletter
...
read more2012 Newsletter
...
read more